查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018738

骨質疏鬆症治療和骨折癒合市場：按治療方法、給藥途徑、骨折類型和最終用戶分類－2026年至2032年全球市場預測

Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route Of Administration, Fracture Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，骨質疏鬆症治療和骨折癒合市場價值將達到 162.8 億美元，到 2026 年將成長至 177.2 億美元，到 2032 年將達到 293.5 億美元，年複合成長率為 8.77%。

主要市場統計數據
基準年 2025 162.8億美元
預計年份：2026年 177.2億美元
預測年份 2032 293.5億美元
複合年成長率 (%) 8.77%

簡要概述影響骨質疏鬆症治療和骨折癒合路徑的臨床重點、治療方法演變和交付模式趨勢。

骨質疏鬆症和骨折癒合在全球老化社會的醫療保健策略和治療創新挑戰中佔據核心地位。隨著人口結構變化導致高風險族群不斷增加，臨床路徑、保險公司預期和醫療服務模式也在同步演變。本文概述了影響臨床醫生、醫院系統、保險公司和製造商決策的臨床需求和商業性現實。

生物製劑、以病人為中心的管理、精準醫療路徑和供應彈性如何重塑治療策略和商業模式。

骨質疏鬆症和骨折癒合的治療和商業性格局正經歷多重同步且加速的變化，這些變化正在重塑臨床實踐和競爭格局。首先，單株抗體療法和成骨藥物的成熟，正促使治療方案的討論焦點轉向快速降低骨折風險和促進骨形成的策略，從而促使臨床醫生重新審視其以往僅依賴抗吸收藥物的傳統方法。

評估 2025 年關稅調整對骨質疏鬆症護理供應鏈、採購和治療整體的營運和策略影響。

2025年關稅調整和貿易政策變更的實施，為骨質疏鬆症治療和骨折癒合產品領域的相關人員帶來了新的成本和供應方面的考量。對藥品原料和成品徵收關稅可能會增加某些藥物類別的到貨成本，特別是那些需要複雜生物製造原料或依賴海外特殊成分的藥物。這反過來又會影響醫院系統和專科診所的定價談判、籌資策略和庫存管理決策。

我們分析治療區域、給藥途徑、臨床環境和骨折特定需求，以將臨床證據與商業性策略結合，從而更有效地實施。

對市場細分進行精確分析，可以揭示臨床需求、商業性機會和營運摩擦之間的交集。將這些細分市場的特徵轉化為可執行的策略至關重要。根據治療方法類型，該領域涵蓋了從傳統的抗骨吸收藥物（如雙膦酸鹽，其又細分為阿崙膦酸鈉、Ibandronate sodium、利塞膦酸鈉和Zoledronic acid等藥物）到荷爾蒙補充療法（包括聯合荷爾蒙療法和以雌激素為中心的療法）等。單株抗體療法包括Denosumab和羅莫索單抗，其中Denosumab根據適應症以普羅利亞和Xgeva等商品名上市。副甲狀腺素類似物包括阿巴洛帕肽和特立帕肽。選擇性雌激素受體調節（如Bazedoxifene和Raloxifene）在特定患者群體中繼續佔據一定的市場地位。治療方法的這些差異導致了臨床應用上的差異，這取決於療效、安全性考慮、患者的合併症以及他們在保險覆蓋範圍清單上的位置。

美洲、歐洲、中東和非洲以及亞太地區在法規、報銷和交付系統方面的區域差異決定了准入和部署途徑。

區域趨勢持續影響骨質疏鬆症治療和骨折管理方案的取得、報銷和臨床應用模式。在美洲，整合式醫療服務體系、以支付主導的處方藥清單流程，以及日益重視與骨折減少和再入院率降低等結果掛鉤的價值導向型契約，都在影響著市場需求。這些壓力促使製藥公司在真實臨床環境中驗證藥物療效，並與醫療系統合作進行上市後實證研究和病患支持計畫。

以生物製藥創新、生命週期管理、夥伴關係和綜合服務交付為中心的競爭策略，塑造產品發展軌跡。

骨質疏鬆症和骨折癒合領域的企業策略涵蓋範圍廣泛，從產品組合多元化和生物製藥創新到生命週期管理和服務整合。一些領先的創新企業正致力於單株抗體和促骨形成（骨生成）平台的研發，利用差異化的臨床特徵來確保在醫保覆蓋範圍和專家採納方面佔據主導地位。這些機構正大力投資於長期安全性監測、直接對照試驗和大規模觀察性研究，以維持臨床醫生的信心並推動指南的採納。

以證據生成、供應彈性、以病人為中心的服務體系和新的商業模式為重點的可行策略方法，以確保競爭優勢。

產業領導企業應共同採取一系列策略行動，以協調臨床差異化、營運韌性和支付方期望。首先，優先創建真實世界數據 (REW) 和療效比較數據，以展現臨床獲益和系統層面的價值，從而增強與支付方的議價能力，並促進其融入基於指南的診療路徑。其次，投資於供應鏈多元化和分階段近岸外包，以降低關稅和貿易中斷帶來的風險，同時透過完善的供應商選擇流程確保品質和合規性。

採用整體性、經專家驗證的檢驗研究途徑，結合主要臨床和支付方訪談，並嚴格整合次要證據和情境分析。

本分析的調查方法整合了多方面的證據、專家檢驗和迭代三角測量，以得​​出切實可行的見解。主要研究包括對內分泌科和整形外科臨床專家、醫院藥劑師、專科診所管理人員以及支付方和採購負責人進行結構化訪談和諮詢，以直接了解處方行為、藥物選擇決策和醫療服務限制等方面的情況。

全面的見解表明，透過將治療創新、交付系統轉型和營運韌性聯繫起來，可以清楚地展現出在骨折預防和癒合方面實現持續有效性的途徑。

總而言之，由於治療創新、醫療服務模式的演變以及新的供應鏈和貿易政策考量，骨質疏鬆症治療和骨折癒合領域正處於轉折點。合成代謝類固醇和單株抗體療法的興起正在重塑臨床決策，而藥物依從性和給藥途徑的變化趨勢也持續影響臨床實務中的療效。同時，關稅帶來的供應鏈挑戰以及支付方日益重視療效，正在重塑商業化策略和產業計畫。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 骨質疏鬆症治療與骨折癒合市場：依治療方法

  • 雙磷酸鹽製劑
    • 阿崙膦酸鈉
    • Ibandronate sodium
    • 利塞膦酸鈉
    • Zoledronic acid
  • 荷爾蒙補充療法
    • 聯合荷爾蒙療法
    • 雌激素療法
  • 單株抗體
    • Denosumab
      • 普羅利亞
      • Xgeva
    • 羅莫索單抗
  • 副甲狀腺素類似物
    • 阿巴洛帕拉肽
    • 特立帕肽
  • 選擇性雌激素受體調節
    • Bazedoxifene
    • Raloxifene

第9章 骨質疏鬆症治療與骨折癒合市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第10章 骨質疏鬆症治療與骨折癒合市場：依骨折類型分類

  • 髖關節
  • 脊椎
  • 手腕

第11章 骨質疏鬆症治療與骨折癒合市場：依最終使用者分類

  • 居家醫療
  • 醫院
  • 專科診所

第12章 骨質疏鬆症治療與骨折癒合市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 骨質疏鬆症治療與骨折癒合市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 骨質疏鬆症治療與骨折癒合市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國骨質疏鬆症治療與骨折癒合市場

第16章：中國骨質疏鬆症治療與骨折癒合市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Healthy Life Pharma Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Private Limited
  • Sanofi SA
  • Taj Pharmaceuticals
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals Industries Ltd
Product Code: MRR-CA17E905EAC5

The Anti-Osteoporosis Therapy & Fracture Healing Market was valued at USD 16.28 billion in 2025 and is projected to grow to USD 17.72 billion in 2026, with a CAGR of 8.77%, reaching USD 29.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.28 billion
Estimated Year [2026] USD 17.72 billion
Forecast Year [2032] USD 29.35 billion
CAGR (%) 8.77%

A concise framing of clinical priorities, therapeutic evolution, and delivery model dynamics shaping anti-osteoporosis care and fracture healing pathways

Osteoporosis and fracture healing occupy a central position in aging-population healthcare strategies and in therapeutic innovation agendas worldwide. As demographic shifts continue to expand the population at risk, clinical pathways, payer expectations, and delivery models are evolving concurrently. This introduction frames the clinical imperatives and commercial realities that shape decisions by clinicians, hospital systems, payers, and manufacturers.

Contemporary management of low bone mass and fragility fractures relies on an interplay of pharmacologic agents, device-facilitated interventions, and coordinated care pathways that prioritize secondary prevention. In parallel, longer-term therapy adherence, route-of-administration preferences, and the emergence of novel biologics are reshaping treatment algorithms. Regulatory approvals, safety communications, and real-world evidence are influencing prescriber confidence and formulary placement in distinct ways across regions.

Against this backdrop, stakeholders must balance clinical efficacy with operational feasibility, recognizing that successful fracture prevention and healing programs demand integration across primary care, specialty clinics, hospitals, and homecare services. This introduction sets the stage for a strategic reading of subsequent sections that analyze transformative industry shifts, trade policy impacts, segmentation intelligence, regional dynamics, competitor activity, and pragmatic recommendations for leaders aiming to convert insight into action.

How biologics, patient-centric administration, precision care pathways, and supply resilience are remapping therapeutic strategies and commercial models

The therapeutic and commercial landscape for osteoporosis and fracture healing is undergoing several concurrently accelerating shifts that are transforming clinical practice and competitive positioning. First, the maturation of monoclonal antibody therapeutics and anabolic agents has redirected treatment sequencing conversations toward rapid fracture risk reduction and bone formation strategies, prompting clinicians to reassess long-standing reliance on antiresorptives alone.

Second, patient-centric care models and adherence-aware device innovations are elevating the importance of route of administration and dosing convenience. Injectable regimens that offer infrequent dosing intervals are changing adherence profiles relative to daily or weekly oral therapies, and this dynamic is prompting payers and providers to reconsider care pathways and support services. Third, the intersection of precision medicine and digital health is enabling more granular risk stratification, with imaging biomarkers and integrated fracture liaison services improving case-finding and timely intervention.

Finally, supply chain resilience and biosimilar competition are emerging as strategic variables in commercial planning. Manufacturers are adapting by diversifying portfolios, pursuing lifecycle management for established agents, and accelerating partnerships that integrate clinical services, diagnostics, and patient support. These transformative shifts are collectively increasing the complexity of commercialization while creating differentiated pathways for organizations that align clinical benefit with operational scalability.

Evaluating the operational and strategic consequences of 2025 tariff adjustments on supply chains, procurement, and therapeutic access across osteoporosis care

The introduction of tariff changes and trade policy adjustments in 2025 has introduced novel cost and supply considerations for stakeholders involved in anti-osteoporosis therapies and fracture-healing products. Tariffs on pharmaceutical inputs and finished goods can increase landed costs for certain therapeutic classes, particularly those with complex biologic manufacturing inputs or reliance on specialized components sourced internationally. This, in turn, affects pricing negotiations, procurement strategies, and inventory management decisions across hospital systems and specialty clinics.

Manufacturers and distributors are responding by re-evaluating global manufacturing footprints, increasing nearshoring investments, and accelerating qualification of alternative API and component suppliers to preserve continuity of supply. In parallel, payers and integrated health systems are intensifying scrutiny of cost-effectiveness and may prioritize therapies with stable supply chains and transparent cost structures. These trends create both headwinds and opportunities: while tariffs introduce short-term margin pressure and procurement complexity, they also incentivize investments in resilient manufacturing, vertical integration, and strategic supplier alliances that can reduce exposure to future trade disruptions.

Moreover, regulatory agencies and customs authorities are placing greater emphasis on documentation and traceability, which requires enhanced coordination between quality, regulatory affairs, and commercial teams. For innovators and established product owners alike, proactive supply chain scenario planning and engagement with procurement stakeholders will be essential to mitigate the cumulative operational impact of tariff shifts and to maintain clinician and patient access to critical therapies.

Dissecting therapy classes, administration routes, care settings, and fracture-specific needs to align clinical evidence and commercial tactics for better adoption

A nuanced reading of market segmentation illuminates where clinical needs, commercial opportunity, and operational friction converge, and it is essential to translate those segment-level characteristics into actionable tactics. Based on therapy type, the landscape spans classic antiresorptives such as bisphosphonates, which are further differentiated into agents like alendronate, ibandronate, risedronate, and zoledronic acid, alongside hormone replacement therapies that include combined hormone options and estrogen-focused strategies. Monoclonal antibody treatments are represented by denosumab and romosozumab, with denosumab delivered under branded indications such as Prolia and Xgeva, while parathyroid hormone analogues include abaloparatide and teriparatide. Selective estrogen receptor modulators such as bazedoxifene and raloxifene continue to occupy niche positions in specific patient cohorts. These therapy distinctions drive differential clinical adoption based on efficacy profiles, safety considerations, patient comorbidities, and formulary positioning.

When considering route of administration, injectable and oral pathways must be weighed against patient convenience, adherence implications, and healthcare delivery capacity; injectable options that can be administered intravenously or subcutaneously often require facility-based resources or trained homecare services, whereas oral agents offer outpatient convenience but face adherence challenges. Examining end users, service delivery occurs across homecare environments, hospitals, and specialty clinics, each with unique procurement, administration, and reimbursement dynamics that influence product selection and support requirements. Fracture type segmentation highlights clinical priority areas-hip, spinal, and wrist fractures-where differences in morbidity, acute care needs, and rehabilitation pathways inform therapeutic urgency and secondary prevention strategies. Taken together, these segmentation lenses should inform targeted clinical evidence generation, tailored patient support programs, and channel-specific commercial tactics to optimize uptake and patient outcomes.

Regional regulatory, reimbursement, and delivery contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and adoption pathways

Regional dynamics continue to shape access, reimbursement, and clinical adoption patterns for osteoporosis therapies and fracture management solutions. In the Americas, demand is influenced by integrated healthcare delivery systems, payer-driven formulary processes, and growing emphasis on value-based contracts tied to outcomes such as fracture reduction and reduced hospital readmissions. These pressures encourage manufacturers to demonstrate real-world effectiveness and to partner with health systems on post-launch evidence generation and patient support programs.

In Europe, Middle East & Africa, regulatory harmonization, national procurement frameworks, and variable reimbursement environments create a mosaic of entry strategies. Country-level differences in pricing negotiation mechanisms and health technology assessment approaches require tailored market access planning and local evidence that addresses specific clinical and economic endpoints. The region also presents opportunities for centralized clinical collaborations and regional manufacturing investments that can improve supply security.

Asia-Pacific markets present diverse trajectories ranging from rapidly expanding access to advanced biologics in high-income urban centers to growing primary care capacity in emerging markets. Local regulatory pathways, rising clinical trial activity, and increasing investment in diagnostic infrastructure are shaping faster adoption of innovative agents in some markets, while in others cost and logistics remain significant barriers. Across all regions, cross-border collaboration on best-practice fracture liaison services and telehealth-enabled monitoring is becoming a differentiator in achieving better patient outcomes and broader therapy penetration.

Competitive strategies centered on biologic innovation, lifecycle management, partnerships, and integrated service offerings that shape product trajectories

Company strategies in the osteoporosis and fracture healing domain reveal a spectrum of approaches, from portfolio diversification and biologic innovation to lifecycle management and service integration. Some leading innovators concentrate on advancing monoclonal antibody and anabolic platforms, leveraging differentiated clinical profiles to secure premium formulary positions and specialist uptake. These organizations invest heavily in long-term safety monitoring, head-to-head comparative trials, and large-scale observational studies to sustain clinician confidence and to inform guideline inclusion.

At the same time, companies with established small-molecule portfolios prioritize cost-containment strategies, manufacturing optimization, and patient support services that improve adherence. Partnerships across diagnostic providers, homecare operators, and digital health firms are increasingly common as firms seek to offer bundled solutions that address the full continuum of fracture prevention and healing. Biosimilar entrants and contract manufacturers are influencing pricing dynamics and supply flexibility, which compels originator companies to accelerate innovation and to explore novel commercial models such as outcome-based pricing.

Across the competitive landscape, intellectual property management, regulatory lifecycle planning, and geographic diversification of manufacturing are recurrent themes. Firms that combine robust clinical evidence, resilient supply chains, and integrated service offerings are positioned to maintain competitiveness, while those that fail to adapt to evolving payer requirements or patient expectations risk erosion of uptake in key channels.

Actionable strategic initiatives emphasizing evidence generation, supply resilience, patient-centered delivery, and novel commercial models to secure competitive advantage

Industry leaders should adopt a coordinated set of strategic actions that align clinical differentiation with operational resilience and payer expectations. First, prioritize generation of real-world evidence and comparative effectiveness data that demonstrate both clinical benefit and systems-level value, enabling stronger negotiations with payers and inclusion in guideline-driven care pathways. Second, invest in supply chain diversification and incremental nearshoring to reduce exposure to tariff and trade disruptions, while ensuring that quality and regulatory compliance are preserved through robust supplier qualification processes.

Third, design patient-centric support programs and administration pathways that reconcile the convenience of oral agents with the adherence advantages of infrequent injectable regimens; incorporate telehealth, nursing support, and digital reminders to improve persistence. Fourth, pursue strategic collaborations with diagnostic providers and fracture liaison services to strengthen case-finding and secondary prevention workflows, thereby improving outcomes and reinforcing value-based contracting opportunities. Fifth, consider adaptive commercial models such as risk-sharing agreements and bundled payments for fracture care that align incentives across stakeholders.

Finally, embed regulatory and health technology assessment planning early in product development and life-cycle activities to expedite access and to address payer evidence requirements proactively. By aligning clinical, operational, and commercial priorities, leaders can convert emerging trends into sustainable competitive advantage.

An integrated, expert-validated research approach combining primary clinical and payer interviews with rigorous secondary evidence synthesis and scenario analysis

The research methodology underpinning this analysis integrates multi-source evidence, expert validation, and iterative triangulation to produce actionable insights. Primary research comprised structured interviews and advisory consultations with clinical specialists in endocrinology and orthopedics, hospital pharmacy directors, specialty clinic administrators, and payer and procurement representatives, providing direct perspectives on prescribing behavior, formulary decision-making, and care delivery constraints.

Secondary research included systematic review of regulatory approvals, peer-reviewed clinical literature, guideline statements, product labels, and publicly available safety communications to ensure alignment with the most recent clinical and regulatory developments. Real-world evidence sources such as health services utilization reports, clinical registries, and published outcomes research were examined to contextualize therapeutic performance and post-market experiences.

Data synthesis relied on cross-validation between primary insights and secondary datasets, with thematic coding used to identify recurrent opportunities and risks. Scenario analysis and sensitivity testing were employed to evaluate the operational impact of supply chain and trade policy changes. Throughout the research process, quality assurance protocols ensured source traceability and consistency, and subject-matter experts reviewed draft findings to confirm clinical plausibility and commercial relevance.

Summative insights that link therapeutic innovation, delivery transformation, and operational resilience into a clear pathway for sustained impact in fracture prevention and healing

In conclusion, the anti-osteoporosis therapy and fracture healing landscape is at an inflection point driven by therapeutic innovation, evolving care delivery models, and emerging supply chain and trade policy considerations. The ascent of anabolic and monoclonal antibody therapies is redefining clinical decision-making, while adherence and route-of-administration dynamics continue to influence real-world effectiveness. Meanwhile, tariff-induced supply chain considerations and growing payer emphasis on outcomes are reshaping commercialization tactics and operational planning.

Stakeholders who proactively integrate robust evidence generation, flexible manufacturing and sourcing strategies, and patient-centered delivery models will be better positioned to navigate this complex environment. Cross-sector collaborations that link diagnostics, digital health, and care coordination services have the potential to improve case-finding and reduce downstream fracture burden. Ultimately, the organizations that align scientific differentiation with demonstrable health-system value and resilient operations will capture durable opportunities in both established and emerging markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Therapy Type

  • 8.1. Bisphosphonates
    • 8.1.1. Alendronate
    • 8.1.2. Ibandronate
    • 8.1.3. Risedronate
    • 8.1.4. Zoledronic Acid
  • 8.2. Hormone Replacement Therapy
    • 8.2.1. Combined Hormone Therapy
    • 8.2.2. Estrogen Therapy
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Denosumab
      • 8.3.1.1. Prolia
      • 8.3.1.2. Xgeva
    • 8.3.2. Romosozumab
  • 8.4. Parathyroid Hormone Analogues
    • 8.4.1. Abaloparatide
    • 8.4.2. Teriparatide
  • 8.5. Selective Estrogen Receptor Modulators
    • 8.5.1. Bazedoxifene
    • 8.5.2. Raloxifene

9. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral

10. Anti-Osteoporosis Therapy & Fracture Healing Market, by Fracture Type

  • 10.1. Hip
  • 10.2. Spinal
  • 10.3. Wrist

11. Anti-Osteoporosis Therapy & Fracture Healing Market, by End User

  • 11.1. Homecare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Anti-Osteoporosis Therapy & Fracture Healing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Osteoporosis Therapy & Fracture Healing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Osteoporosis Therapy & Fracture Healing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anti-Osteoporosis Therapy & Fracture Healing Market

16. China Anti-Osteoporosis Therapy & Fracture Healing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amgen Inc.
  • 17.6. Eli Lilly and Company
  • 17.7. F. Hoffmann-La Roche Ltd.
  • 17.8. GlaxoSmithKline plc
  • 17.9. Healthy Life Pharma Pvt. Ltd.
  • 17.10. Johnson & Johnson Services, Inc.
  • 17.11. Manus Aktteva Biopharma LLP
  • 17.12. Merck & Co., Inc.
  • 17.13. Novartis AG
  • 17.14. Pfizer Inc.
  • 17.15. Salvavidas Pharmaceutical Private Limited
  • 17.16. Sanofi S.A.
  • 17.17. Taj Pharmaceuticals
  • 17.18. Taj Pharmaceuticals Limited
  • 17.19. Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO